Roads to Advanced Vaccines: Influenza Case Study

Overview

Journal Microb Biotechnol

Specialties Biotechnology
Microbiology

Date 2017 Aug 16

PMID 28809451

Citations 3

Authors

Peggy Riese

Carlos A Guzman

Affiliations

Soon will be listed here.

Abstract

Vaccines represent a cornerstone to ensure healthy lives and promote well-being for all at all ages. However, there are many diseases for which vaccines are not available, are relatively ineffective or need to be adapted periodically. Advances in microbial biotechnology will contribute to overcoming these roadblocks by laying the groundwork for improving and creating new approaches for developing better vaccines, as illustrated here in the case of influenza.

Citing Articles

Using the Past to Maximize the Success Probability of Future Anti-Viral Vaccines.

Serwer P Vaccines (Basel). 2020; 8(4).

PMID: 33019507 PMC: 7712378. DOI: 10.3390/vaccines8040566.

Next Generation Influenza Vaccines: Looking into the Crystal Ball.

Guzman C Vaccines (Basel). 2020; 8(3).

PMID: 32825635 PMC: 7563445. DOI: 10.3390/vaccines8030464.

Roads to advanced vaccines: influenza case study.

Riese P, Guzman C Microb Biotechnol. 2017; 10(5):1036-1040.

PMID: 28809451 PMC: 5609253. DOI: 10.1111/1751-7915.12835.

References

Giles B, Bissel S, DeAlmeida D, Wiley C, Ross T . Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol. 2011; 19(2):128-39. PMC: 3272934. DOI: 10.1128/CVI.05533-11. View

Tsai T . Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother. 2013; 45(2):159-74. PMC: 3780956. DOI: 10.3947/ic.2013.45.2.159. View

de Vries R, Rimmelzwaan G . Viral vector-based influenza vaccines. Hum Vaccin Immunother. 2016; 12(11):2881-2901. PMC: 5137548. DOI: 10.1080/21645515.2016.1210729. View

Gomez Lorenzo M, Fenton M . Immunobiology of influenza vaccines. Chest. 2013; 143(2):502-510. PMC: 3619640. DOI: 10.1378/chest.12-1711. View

Altenburg A, Rimmelzwaan G, de Vries R . Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine. 2014; 33(4):500-6. DOI: 10.1016/j.vaccine.2014.11.054. View

Milian E, Kamen A . Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015; 2015:504831. PMC: 4359798. DOI: 10.1155/2015/504831. View

DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371(7):635-45. DOI: 10.1056/NEJMoa1315727. View

Yen C, Hyde T, Costa A, Fernandez K, Tam J, Hugonnet S . The development of global vaccine stockpiles. Lancet Infect Dis. 2015; 15(3):340-7. PMC: 4712379. DOI: 10.1016/S1473-3099(14)70999-5. View

Nakaya H, Wrammert J, Lee E, Racioppi L, Marie-Kunze S, Nicholas Haining W . Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011; 12(8):786-95. PMC: 3140559. DOI: 10.1038/ni.2067. View

10.

Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D . Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2016; 35(4):513-520. DOI: 10.1016/j.vaccine.2016.12.011. View

11.

Khurana S, Loving C, Manischewitz J, King L, Gauger P, Henningson J . Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013; 5(200):200ra114. DOI: 10.1126/scitranslmed.3006366. View

12.

Sobolev O, Binda E, OFarrell S, Lorenc A, Pradines J, Huang Y . Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. 2016; 17(2):204-13. PMC: 6485475. DOI: 10.1038/ni.3328. View

13.

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G . Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011; 30(12):1081-5. DOI: 10.1097/INF.0b013e3182367662. View

14.

Wilkinson T, Li C, Chui C, Huang A, Perkins M, Liebner J . Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18(2):274-80. DOI: 10.1038/nm.2612. View

15.

Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, Wortley P, Weintraub E . The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25(27):5086-96. DOI: 10.1016/j.vaccine.2007.03.046. View

16.

Castrucci M . Factors affecting immune responses to the influenza vaccine. Hum Vaccin Immunother. 2017; 14(3):637-646. PMC: 5861809. DOI: 10.1080/21645515.2017.1338547. View

17.

Kennedy R, Ovsyannikova I, Haralambieva I, Oberg A, Zimmermann M, Grill D . Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination. Front Immunol. 2016; 7:450. PMC: 5089977. DOI: 10.3389/fimmu.2016.00450. View

18.

Song J, Cheong H, Noh J, Seo Y, Choi W, Cho G . Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol. 2013; 85(9):1591-7. DOI: 10.1002/jmv.23630. View

19.

Gurwith M, Lock M, Taylor E, Ishioka G, Alexander J, Mayall T . Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013; 13(3):238-50. PMC: 3576519. DOI: 10.1016/S1473-3099(12)70345-6. View

20.

Lang P, Mendes A, Socquet J, Assir N, Govind S, Aspinall R . Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012; 7:55-64. PMC: 3292388. DOI: 10.2147/CIA.S25215. View